Prospects in non-invasive assessment of liver fibrosis: Liquid biopsy as the future gold standard?

Lambrecht, Joeri; Verhulst, Stefaan; Mannaerts, Inge; Reynaert, Hendrik; Grunsven, Leo A. van

doi:10.1016/j.bbadis.2018.01.009

Cited by 46 publications

(43 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 This accumulation can in turn cause distortion of the normal hepatic architecture and ultimately progress to cirrhosis, which is irreversible and causes impaired liver function. 2,3 Noninvasive tests for the diagnosis of liver fibrosis have been developed. Although many direct and indirect surrogate markers for cirrhosis have been suggested, no single surrogate marker is used widely in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Performance of Serum Asialo α<sub>1</sub>-Acid Glycoprotein Levels to Predict Liver Cirrhosis

et al. 2021

View full text Add to dashboard Cite

Background/Aims To date, studies on various noninvasive techniques have been suggested to evaluate the degree of liver fibrosis. We aimed to investigate the diagnostic performance of serum asialo α1-acid glycoprotein (AsAGP) in the diagnosis of liver cirrhosis compared with chronic hepatitis for clinically useful result. Methods We conducted a case-control study of 96 patients with chronic liver disease. Chronic hepatitis was defined as the presence of chronic liver disease on ultrasonography, with a liver stiffness of less than 5.0 kPa as shown on magnetic resonance elastography (MRE). Liver cirrhosis was defined as liver stiffness of more than 5.0 kPa on MRE. The serum AsAGP concentration was compared between the two groups. Results Serum AsAGP levels were significantly higher in patients with cirrhosis than in those with chronic hepatitis (1.83 μg/mL vs 1.42 μg/mL, p<0.001). Additionally, when comparing patients in each cirrhotic group (Child-Pugh grades A, B, and C) to those with chronic hepatitis, AsAGP levels were significantly higher in all the cirrhotic groups (p<0.05, p<0.01, p<0.001, respectively). The sensitivity and specificity of AsAGP for detecting cirrhosis were 79.2% and 64.6%, respectively, and the area under the curve value was 0.733. The best diagnostic cutoff to predict cirrhosis was 1.4 μg/mL. AsAGP and bilirubin were found to be independent risk factors for the prediction of cirrhosis in the logistic regression analysis. Conclusions Serum AsAGP showed an acceptable diagnostic performance in predicting liver cirrhosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic Performance of Serum Asialo α<sub>1</sub>-Acid Glycoprotein Levels to Predict Liver Cirrhosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The implication of these circulating factors to predict liver brosis is becoming more popular because they are available in many laboratories, they are almost non expensive, and can be repeated several times. Moreover, they may be representative of the brosis in the whole liver, thus avoiding small sampling error which is a technical defect in percutaneous liver biopsy [21].…”

Section: Discussionmentioning

confidence: 99%

The protective role of Deferoxamine in the prevention of hepatic fibrosis in children treated with Doxorubicin: a randomized controlled clinical trial

Bordbar

Fathpour

Dehghani

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Hepatic fibrosis is an ominous sign which may follow treatment with Doxorubicin (DOX) chemotherapy. The aim of this study was investigating the protective effect of Deferoxamine (DFO) against hepatic fibrosis in treatment-naïve pediatric cancer patients. Methods: In this prospective randomized controlled trial, 61 treatment-naïve children (2-18 years) with different types of cancer who referred to a tertiary teaching hospital in South of Iran were enrolled. They were randomly assigned to 3 groups; group 1 (control, n=21), group 2 (DFO 10 times DOX dose, n=20), group 3 (DFO 50mg/kg, n=20). DFO was administered as an 8-hour continuous intravenous infusion during and after DOX infusion in each chemotherapy cycle. Non-invasive serum markers of liver fibrosis including APRI, FIB-4 score and Fibro Test were measured in each individual. Besides, hepatic Fibro Scan was used after the last course of chemotherapy to estimate fibrosis degree. Results: Fifty-six patients were analyzed. Alanine aminotransferase was mildly increased in the treatment groups compared to pre-treatment. Treatment with DFO 10 times DOX dose was associated with significant decline in post-treatment APRI (adjusted odds ratio 0.17; 95% confidence interval 0.03- 0.84). METAVIR fibro scores were in the F0-F1 zone in all participants, and the results were comparable in the study groups. No adverse drug effect was reported in the treatment groups. Conclusion: DOX may not lead to severe liver fibrosis if the maximum allowed cumulative dose is not exceeded. DFO at the dose of 10 times of DOX dose may have a potential protective role against liver fibrosis. Larger multi-center studies with longer follow up are warranted to further assess this issue.

show abstract

“…Such invasive procedures are associated with certain complications. The majority of patients refuse to undergo liver biopsy, and they are even more reluctant to accept a second liver biopsy, making it difficult to assess the efficacy of the procedure (14). Additionally, sample errors, and intraobserver or interobserver differences may affect the accuracy of the diagnostic results (15)(16)(17).…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of decoy receptor 3 upregulation in patients with hepatitis B and liver fibrosis

et al. 2018

View full text Add to dashboard Cite

Decoy receptor 3 (DcR3) is a tumor necrosis factor receptor, which may inhibit apoptosis. The aim of the present study was to investigate the clinical significance of DcR3 upregulation in patients with chronic hepatitis B (CHB) and hepatic fibrosis. A total of 128 patients with a clinical diagnosis of CHB who underwent liver biopsy were included in the present study. The expression levels of DcR3, hyaluronic acid (HA), type III procollagen, type IV collagen (IV-C) and laminin protein were assessed. The diagnostic value of DcR3 in patients with CHB with hepatic fibrosis was determined using receiver operating characteristic (ROC) curve analysis. DcR3 was significantly upregulated in patients with CHB, particularly in patients with active CHB. The expression of DcR3 was significantly increased in patients with CHB with liver fibrosis and liver cirrhosis, compared with patients with CHB without liver fibrosis. The area under the ROC curve for the diagnosis of CHB liver fibrosis based on DcR3 or DcR3 combined with IV-C/HA was 0.807 or 0.869, with a sensitivity and specificity of 76.9 and 77.8% or 84.6 and 81.2%, respectively. DcR3 is a marker for liver fibrosis in patients with hepatitis B infection. The use of DcR3 in combination with IV-C and HA may further increase its diagnostic value for liver fibrosis.

show abstract

Prospects in non-invasive assessment of liver fibrosis: Liquid biopsy as the future gold standard?

Cited by 46 publications

References 140 publications

Diagnostic Performance of Serum Asialo α<sub>1</sub>-Acid Glycoprotein Levels to Predict Liver Cirrhosis

Diagnostic Performance of Serum Asialo α<sub>1</sub>-Acid Glycoprotein Levels to Predict Liver Cirrhosis

The protective role of Deferoxamine in the prevention of hepatic fibrosis in children treated with Doxorubicin: a randomized controlled clinical trial

Clinical significance of decoy receptor 3 upregulation in patients with hepatitis B and liver fibrosis

Contact Info

Product

Resources

About